TURMERICIMMUNE Trademark

Trademark Overview

On Wednesday, November 26, 2025, a trademark application was filed for TURMERICIMMUNE with the United States Patent and Trademark Office. The USPTO has given the TURMERICIMMUNE trademark a serial number of 99517204. The federal status of this trademark filing is FINAL REFUSAL - MAILED as of Friday, April 17, 2026. The TURMERICIMMUNE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical drug development services
turmericimmune

General Information

Serial Number99517204
Word MarkTURMERICIMMUNE
Filing DateWednesday, November 26, 2025
Status645 - FINAL REFUSAL - MAILED
Status DateFriday, April 17, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceutical drug development services

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, April 14, 2026
Primary Code042
First Use Anywhere DateWednesday, December 1, 2010
First Use In Commerce DateTuesday, December 1, 2015

Trademark Owner History

Party NameNOT AVAILABLE
Party Type10 - Original Applicant
Legal Entity Type01 - Individual
AddressStaten Island, NY 10314
US

Trademark Events

Event DateEvent Description
Wednesday, November 26, 2025NEW APPLICATION ENTERED
Wednesday, November 26, 2025APPLICATION FILING RECEIPT MAILED
Thursday, February 12, 2026NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, March 31, 2026ASSIGNED TO EXAMINER
Wednesday, April 1, 2026NON-FINAL ACTION WRITTEN
Wednesday, April 1, 2026NON-FINAL ACTION E-MAILED
Wednesday, April 1, 2026NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, April 4, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, April 4, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Sunday, April 5, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 6, 2026NON-FINAL ACTION WRITTEN
Monday, April 6, 2026NON-FINAL ACTION E-MAILED
Monday, April 6, 2026NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 14, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 14, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 15, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 16, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, April 16, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 16, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, April 17, 2026FINAL REFUSAL WRITTEN
Friday, April 17, 2026FINAL REFUSAL E-MAILED
Friday, April 17, 2026NOTIFICATION OF FINAL REFUSAL EMAILED

Related Keywords

turmericimmune services development drug pharmaceutical